Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.69 |
| ▸ | TUBB | P07437 | 4/20 | 0.69 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.69 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.69 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.69 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.69 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.69 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.69 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.69 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.69 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.69 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.69 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.69 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.69 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | MYB | P10242 | 5/20 | 0.54 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429056 | 0.93 | SMN1; SMN2 (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4327959 | 0.85 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1751160 | 0.85 | SMN1; SMN2 (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4322223 | 0.85 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4333394 | 0.85 | TUBB4A (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4332597 | 0.84 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4320572 | 0.84 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4319503 | 0.84 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4429124 | 0.84 | TUBB4A (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4326317 | 0.84 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | claimed |
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | claimed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | claimed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1392683-B1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE AS ANTICANCER AGENTS | CYTOVIA INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7053117-B2 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP5 | TUBB4A 1510/4885TUBB 2350/4885TUBA3C 2231/4885 |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | TUBB4A 1993/4885TUBB 3464/4885TUBA3C 2530/4885 |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP5, CASP1 | TUBB4A 1775/4885TUBB 3356/4885TUBA3C 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.